These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 3479046)

  • 1. Pharmacokinetics of ofloxacin after parenteral and oral administration.
    Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1338-42. PubMed ID: 3479046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
    Höffken G; Lode H; Prinzing C; Borner K; Koeppe P
    Antimicrob Agents Chemother; 1985 Mar; 27(3):375-9. PubMed ID: 3158275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and identification of metabolites of ofloxacin in rats, dogs and monkeys.
    Sudo K; Okazaki O; Tsumura M; Tachizawa H
    Xenobiotica; 1986 Aug; 16(8):725-32. PubMed ID: 3464137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin.
    Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
    J Antimicrob Chemother; 1988 Sep; 22 Suppl C():73-9. PubMed ID: 3182465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
    Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
    Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of ofloxacin in the elderly (65-85 years) with normal renal function after a single oral dose of 200 mg].
    Veyssier P; Fourtillan JB; Modai J; Couet W; Lefebvre MA; Darchis JP; Vincent Du Laurier M; Bryskier A
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):596-9. PubMed ID: 3534750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative bioavailability of ofloxacin tablets in comparison to oral solution.
    Malerczyk V; Verho M; Korn A; Rangoonwala R
    Curr Med Res Opin; 1987; 10(8):514-20. PubMed ID: 3479296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.
    Verho M; Korn A; Badian M; Malerczyk V; Waldhäusl W
    Chemotherapy; 1988; 34(3):170-7. PubMed ID: 3166420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.
    Guay D; Tack K; Flor S
    Int J Clin Pharmacol Res; 1991; 11(5):203-9. PubMed ID: 1814841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a single oral dose of ofloxacin in patients with renal failure.
    Nawishy S; Moukhtar I; Sabbour M
    Chemioterapia; 1986 Dec; 5(6):391-3. PubMed ID: 3467875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Pharmatherapeutica; 1985; 4(6):376-82. PubMed ID: 3866256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
    Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals.
    Girard D; Gootz TD; McGuirk PR
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1671-6. PubMed ID: 1329625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of new quinolones.
    Lode H; Höffken G; Prinzing C; Glatzel P; Wiley R; Olschewski P; Sievers B; Reimnitz D; Borner K; Koeppe P
    Drugs; 1987; 34 Suppl 1():21-5. PubMed ID: 3481323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ofloxacin pharmacokinetics in renal failure.
    Fillastre JP; Leroy A; Humbert G
    Antimicrob Agents Chemother; 1987 Feb; 31(2):156-60. PubMed ID: 3471179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical pharmacology of ofloxacin: a new chemotherapeutic agent belonging to the gyrase inhibitor group].
    Verho M; Dagrosa EE; Malerczyk V
    Infection; 1986; 14 Suppl 1():S47-53. PubMed ID: 3007366
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.